Perfusion Tech ApS: Financial statements 2017
CVR: 38238213
Source: annual report 2017, Danish Business Authority
28/11/2016 – 31/12/2017
Perfusion Tech ApS (CVR 38238213) has filed annual accounts for 2017. In 2017, the company reported a gross profit of DKK -278,036 and a net result of DKK -271,716. Equity in the 2017 report amounted to DKK -214,428.
- Gross Profit
- DKK -278,036
- Profit/Loss
- DKK -271,716
- Equity
- DKK -214,428
- Total Assets
- DKK 311,243
Keep an eye on Perfusion Tech ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
As of October 25, 2017, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Perfusion Tech ApS.
As of October 25, 2017, Jeppe Øvli Øvlesen has joined the board of directors of Perfusion Tech ApS.
As of October 25, 2017, Steffen Boutrup Møller has joined the board of directors of Perfusion Tech ApS.
As of October 25, 2017, Thomas Engelbrecht Nordkild Jonassen has joined the board of directors of Perfusion Tech ApS.
As of October 25, 2017, Morten Asp Vonsild Lund has joined the board of directors of Perfusion Tech ApS.
As of October 25, 2017, Mads Aagaard Linde Madsen has joined the board of directors of Perfusion Tech ApS.
On October 25, 2017, the company changed its name from Perfusion Tech IVS to Perfusion Tech ApS.
About Perfusion Tech ApS
Perfusion Tech ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2016. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Perfusion Tech IVS. The management consists of Declan Cassells. The company is owned by Renew Pharmaceuticals Limited. In 2025, the company reported a gross profit of DKK -6,142,804 and a net result of DKK -12,724,708 compared with DKK -14,469,520 the year before. Equity in the 2025 report amounted to DKK -9,640,655.